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Introduction: Changes in 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) incorporation by tumors, detected using positron emission tomo-
graphy, during response to chemotherapy are utilized clinically in patient management. Here, the effect of treatment with growth-
inhibitory doses of the anti-human epidermal growth factor receptor-2 antibody trastuzumab (Herceptin) on the incorporation of FDG
by breast tumor cells was measured along with hexokinase (HK) and glucose transport to determine the potential of FDG-positron
emission tomography in predicting response to these biological anti-cancer therapies and their modulatory effects on the steps involved in
FDG incorporation.
Methods: The sensitivity to trastuzumab of three breast tumor cell lines, SKBr3, MDA-MB-453 and MDA-MB-468, expressing human
epidermal growth factor receptor-2 at high, medium and low levels, respectively, was determined using MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay over a 6-day period, and a clonogenic assay was carried out after 7- and 10-day exposures. FDG
incorporation by cells treated with growth-inhibitory doses of trastuzumab was carried out after 4 h and 2, 4 and 6 days of treatment. Glucose
transport (rate of uptake of the non-metabolizable analogue [3H]O-methyl-D-glucose), HK activity and lactate production were measured on
cells treated with inhibitory doses of trastuzumab for 6 days.
Results: The IC50 doses for SKBr3 and MDA-MB-453 and the IC20 dose for MDA-MB-468 after 6 days of treatment with trastuzumab were
0.25, 1 and 170 μg/ml, respectively. FDG incorporation by SKBr3 and MDA-MB-453 cells was found to be decreased using IC50 doses of
trastuzumab for 6 days. At the IC50 doses, FDG incorporation was also decreased at 4 days and, in the case of MDA-MB-453, even after 4 h
of treatment. Decreased FDG incorporation corresponded with decreased HK activity in these cells. Lactate production, previously suggested
to be a potential measure of response, was found to be significantly decreased by SKBr3 and MDA-MB-453 cells responding to trastuzumab.
Conclusion: FDG incorporation at the tumor cell level is modulated by treatment with growth-inhibitory doses of trastuzumab due to
modulation of HK activity. Changes in lactate production may also be a useful determinant of response to trastuzumab.
© 2011 Elsevier Inc. All rights reserved.Keywords: Trastuzumab; FDG; PET; Hexokinase; Lactate1. Introduction
The human epidermal growth factor receptor (HER)
tyrosine kinase family consists of four members (HER-1–
HER-4) involved in controlling cellular events, including⁎ Corresponding author. Tel.: +44 01224 553208.
E-mail address: t.smith@abdn.ac.uk (T.A.D. Smith).
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doi:10.1016/j.nucmedbio.2010.09.005cell proliferation, differentiation and cell death. The
amplification of HER-2 (ErbB2/neu), observed in several
cancer types [1], is associated with resistance to apoptosis,
enhanced proliferation, cell migration and invasiveness.
About 25% of cases of breast cancer exhibit HER-2
overexpression, which is strongly associated with poor
prognosis [2]. These patients derive clinical benefit from
treatment with the HER-2-targeting antibody trastuzumab
(Herceptin) [3]. However, trastuzumab is very expensive,
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especially when administered with anthracyclines. Further-
more, HER-2-negative cells have been shown to exhibit little
or no response to the drug [5].
It is recommended [6] that overexpression of HER-2
should be evaluated on every primary breast cancer to predict
which patients may benefit from trastuzumab. This is
determined using either fluorescent in situ hybridization or
immunohistochemistry on biopsy specimens taken from the
primary tumor. However, this approach may not provide
globally representative information on either the primary
tumor or metastasis, which can exhibit an HER-2 status
different from the primary tumor [7], or the likelihood of its
response to trastuzumab.
An alternative approach to tumor therapy response
prediction is the use of positron emission tomography
(PET) to monitor changes in tracer incorporation during the
course of treatment. 2-[18F]-Fluoro-2-deoxy-D-glucose
(FDG) is the most commonly utilized PET tracer with
availability at all PET centers. The use of serial FDG-PET
scans in cancer patients during the course of chemotherapy
has been demonstrated by many studies to be a useful tool in
cancer management [8]. Generally, compared with pre-
treatment, responding tumors show decreased FDG uptake
within a few days of starting chemotherapy. Two recent
studies of human tumor xenografts [9,10] have produced
conflicting findings regarding the effect of response to
trastuzumab on FDG incorporation. McLarty et al. [9]
showed that treatment of MDA-MB-361 cells, which
overexpress HER-2, exhibited a decline in FDG incor-
poration, whereas MDA-MB-231 cells, which do not
overexpress HER-2, showed no change in FDG incorpora-
tion. However, in the study by Shah et al. [10], FDG
incorporation by trastuzumab-treated MMTV/HER-2 and
BT474 cells was found not to accompany response.
Neither study carried out in vitro studies to assist in under-
standing the effect of trastuzumab FDG incorporation at
the tumor cell level.
To understand the importance of time and dose of anti-
HER-2 antibodies on FDG incorporation at the tumor cell
level, we have measured FDG incorporation in the breast
tumor cells SKBr3 [which overexpress HER-2 at a high
level (900 ng/mg)], MDA-MB-453 [which overexpress
HER-2 at a medium level (100 ng/ml)] and MDA-MB-468
(which do not overexpress HER-2) [11] at various time
points during treatment with growth-inhibitory doses of
trastuzumab. Akt is a downstream effector of HER-2 and is
known to influence the activity of hexokinase (HK) [12]
and mitochondrial membrane potential. Therefore, we
determined HK activity and lactate production during
treatment with trastuzumab. Glucose transport was also
measured due to its important role in FDG uptake. Growth
inhibition was determined using MTT [3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide] assays and ver-
ified using the clonogenic assay, the gold standard for
measuring therapeutic efficacy.2. Materials and methods
All chemicals were obtained from Sigma-Aldrich (Poole,
UK) unless otherwise stated. Cell lines were obtained from
American Type Culture Collection (Manassas, VA, USA).
2.1. Cells and treatments
SKBr3, MDA-MB-453 and MDA-MB-468 cells were
cultured in DMEM (with Glutamax) (Invitrogen, Paisley,
UK) and supplemented with 50 U/ml of penicillin, 50 μg/ml
of streptomycin and 10% fetal bovine serum. During drug
incubation periods for the FDG uptake, glucose transport,
HK and lactate assays, media changes were carried out on
Day 4.
2.2. Cell viability
2.2.1. MTT assay
Cells were grown until confluent in 75-cm2 flasks, and
after trypsinization and addition of medium, the cell numbers
were corrected to 15,000/ml for the SKBr3 and MDA-MB-
453 cells and 7500/ml for the faster-growing MDA-MB-468
cells. One hundred microliters of cell suspension was seeded
into 96-well plates, and the plates were incubated at 37°C
overnight. Medium (100 μl) supplemented with varying
concentrations of trastuzumab to produce final concentra-
tions within the ranges of 0.001–0.25 μg/ml for SKBr3,
0.025–5 μg/ml for MDA-MB-453 and 1–250 μg/ml for
MDA-MB-468 was then added to each well (200 μl/well in
total), and the plate was returned to the incubator. A
background of 200 μl of medium and a control of 200 μl of
medium and cells were also set up. After 6 days, 50 μl of
MTT was added to each of the wells and incubated for 3–4 h.
The media were then aspirated using a syringe, and 200 μl
of dimethylsulfoxide was then added to each well. Each
plate was then placed in a scanning multi-well spectropho-
tometer (Dynatech MR5000, Dynatech Laboratories, Chan-
tilly, VA, USA) and agitated for 30 s prior to measuring
spectrophotometric absorbance at 570 nm (test filter=570
nm, reference filter=690 nm). The plates were analyzed
using Biolinx 2.0 software (Biolinx 2.0, Dynatech Labora-
tories). The absorbance at each treatment concentration
was calculated as a percentage of that for the control cells.
The MTT assay was carried out in four separate experiments,
the data were pooled and a curve of trastuzumab concentra-
tion vs. relative absorbance was used to determine IC values
(Fig. 1).
2.2.2. Colony formation
The ability of SKBr3 and MDA-MB-453 cells treated
continuously with trastuzumab (IC20 and IC50) and MDA-
MB-468 cells treated with trastuzumab (IC10 and IC20) to
proliferate was determined by seeding cells into 25-cm2
tissue culture flasks (20,000 per flask) and determining the
number of cells that form colonies of at least 25 cells after
7 days and at least 50 cells by 10 days (results are expressed
relative to the number in control flasks). Colony counts were
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Fig. 1. MTT incorporation (absorbance at 570 nm) relative to untreated
cells (%) by SKBr3 cells treated for 6 days with a range of concentrations
of trastuzumab.
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microscope with a 10× objective lens (individual cells
could be clearly seen using this lens) counting cells in 20
fields per flask. The total colonies per flask were then
expressed as the percentage of total colonies formed in the
control flasks. Controls and all treatments were set up with
four replicates.
2.2.3. FDG incorporation
Cells were seeded in 25-cm2 tissue culture flasks and
3 days later treated with requisite doses of trastuzumab for
4 h, 2 days, 4 days and 6 days. At the time of FDG uptake
determination, medium was replaced with 1 ml of fresh
medium [glucose concentration=1 mg/ml (5 mM), as this is
about the same glucose concentration found in serum from a
non-diabetic subject] containing 37 KBq of FDG and
incubated for 20 min at 37°C. Cells were then washed five
times with 5 ml of ice-cold PBS and detached by addition of
trypsin. After addition of medium to neutralize the trypsin,
0.8 ml of cell suspension was transferred into microcen-
trifuge (Eppendorf) tubes for determination of FDG uptake
in a well counter. The cells were then centrifuged and
washed with 1 ml of PBS, the pellet was dissolved in 0.1 ml
NaOH (1 M) and protein content was determined after
neutralizing with 0.1 ml HCl. Protein content was deter-
mined using a bicinchoninic acid protein assay kit (Sigma,
Poole, UK). The uptake of FDG was normalized by dividing
by protein content. Uptake by treated cells was then
expressed as the percentage of uptake by control cells.
2.2.4. Glucose transport
Glucose transport rate was determined by incubating cells
with [3H]O-methyl-D-glucose ([3H]OMG), and the amount
taken up before equilibrium occurred was considered to be a
measure of glucose transport, determined.
Flasks of cells were seeded as for FDG uptake. At the
time of glucose transport determination, medium was
removed and replaced with fresh medium (glucose concen-
tration=1 mg/ml) containing 37 KBq of [3H]OMG and
0.1 mM “cold” OMG for 5 and 10 s. The incubation was
ended by rapid addition of 5 ml of ice-cold PBS containing
the glucose transport inhibitor phloretin (0.1 mM) followedby three further rapid washes. Cells were then trypsinized,
half of them added to 5 ml of Optima Gold scintillation fluid
(Perkin Elmer, UK), and [3H]OMG uptake was determined
in a scintillation counter. The remaining cells were prepared
for protein assay. The uptake of [3H] during the 5- and 10-s
periods was normalized by dividing by total protein content
of cells in each flask. Values for the treated cells were then
expressed as the percentage of uptake by control cells.
2.2.5. HK activity
Cells were seeded in 75-cm2 flasks and after treatment
with trastuzumab for 6 days harvested by trypsinization.
After addition of medium, they were collected into
microcentrifuge (Eppendorf) tubes, washed with PBS and
centrifuged at 400g for 1 min, and the pellet was resuspended
in 0.2 ml of homogenization buffer (10 mM Tris–HCl, pH
7.7, 0.25 mM sucrose, 0.5 mM dithiothreitol, 1 mM
aminohexanoic acid and 1 mM PMSF). They were then
transferred to a 1-ml glass Dounce homogenizer and
homogenized by 10 strokes at 4°C. The homogenized cells
were transferred to a microcentrifuge tube and centrifuged
for 10 min at 800g to remove cell debris. The supernatant
was transferred to a new microcentrifuge tube, the pellet was
washed with 0.2 ml of homogenization buffer and the
supernatant was pooled. Protein content of the homogenate
was determined on a 20-μl sample.
Enzyme activity was determined by addition of 100 μl
of homogenate to 0.9 ml of assay medium consisting of
100 mM Tris–HCl, pH 8.0, 10 mM glucose, 0.4 mM
NADP+, 10 mM MgCl2, 5 mM ATP and 0.15 U of glucose-
6-phosphate dehydrogenase in a cuvette at 37°C. The
reaction was followed by monitoring the change in
absorbance at 340 nm due to the formation of NADPH.
The change in absorbance was normalized by dividing by
protein content of the homogenate. HK activity by treated
cells was then expressed as the percentage of HK activity of
control cells.
2.2.6. Lactate production
Cells were set up and treated for 6 days as for glucose
uptake determination. The cells were then washed with PBS
(4×) and then incubated for 30 min with DMEM medium
(containing 1 mg/ml of glucose). The medium was then
removed and stored at −20°C until lactate was assayed. Cells
were then trypsinized and prepared for protein assay as for
FDG incorporation. Lactate was assayed in the medium
using a lactate assay kit (BioVision, CA, USA) following the
manufacturer's directions. Lactate concentration in nano-
moles produced during the 30-min incubation was normal-
ized by dividing by protein content of the flask. Production
of lactate by treated cells was expressed as a percentage of
that by control cells.
2.3. Statistics and replicates
Significant differences between means were established
using Student's t test. Values are included in the text and are
Table 1
Growth-inhibitory doses (μg/ml) for breast tumor cells treated with
trastuzumab for 6 days determined using the MTT assay
SKBr3 MDA-MB-453 MDA-MB-468
IC50 0.25 1 –
IC20 0.005 0.015 170
IC10 – – 5
Table 2
Summary of changes in clonogenic potential after 10 days of treatment and
in FDG incorporation, HK activity, glucose transport and lactate production
after 6 days of treatment with IC50 (SKBr3 and MDA-MB-453) and IC20
(MDA-MB-468) doses of trastuzumab
Cell line Parameter
Colonies FDG HK
activity
Glucose
transport
Lactate
output
SKBr3 ↓ ↓ ↓ nc ↓
MDA-MB-453 ↓ ↓ ↓ ↓ ↓
MDA-MB-468 Nc ↓ ↓ nc nc
nc indicates no change.
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Number of Replicates in Control and Treatment Groups−2;
e.g., if there are four controls and five treated samples, then
the t value is expressed as (t7=x, Pby), and where the
difference between the means is not significant, this is
described by (t7=x, ns)]. Experiments were generally carried
out using four replicates of treated and control flasks such
that the degrees of freedom value is 6. Data from several
experiments were combined in most cases, and this is
reflected in the degrees of freedom.3. Results
3.1. MTT and clonogenic assays
Inhibitory doses for trastuzumab incubated for 6 days
with MDA-MB-468, MDA-MB-453 and SKBr3 breast
tumor cells are shown in Table 1. The maximum achievable
inhibition of MDA-MB-468 with trastuzumab was 20%
using a mean dose (±S.D.) of 170 (±62) μg/ml, whereas the
IC50 doses for MDA-MB-453 and SKBr3 were much lower
at 1 (±1) and 0.25 (±0.11) μg/ml, respectively.
Fig. 2 shows the effects of growth-inhibitory doses of
trastuzumab on the clonogenic potential of each cell line
after 7 and 10 days of continuous exposure to each drug. The
IC20 and IC50 doses of trastuzumab determined using the
MTT assay inhibited the colony-forming ability of SKBr3 by
about 20% (t6=2.77, Pb.05) and 50% (t6=5.12, Pb.01) after
10 days of treatment. The IC50 dose also reduced the colony∗
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Fig. 2. Formation of colonies of N25 cells (Day 7) or N50 cells (Day 10) by SKBr3 (
low (hatched symbols) (IC20 for SKBr3 and MDA-MB-453, IC10 for MDA-MB-4
MB-468) doses of trastuzumab. Data are expressed as the number of colonies in
asterisks indicate significant difference from control at ⁎Pb.05 and ⁎⁎Pb.01.formation by MDA-MB-453 cells (t6=3.07, Pb.05) by about
50% corresponding with the MTT assay. IC10 and IC20 doses
of trastuzumab on MDA-MB-468 cells had almost no effect
on colony formation even after 10 days of treatment [IC10
(t6=0.9, ns) and IC20 (t6=1.3, ns)].
Incorporation of FDG per milligram of protein relative to
untreated controls after treatment of SKBr3 and MDA-MB-
453 cells with IC20 and IC50 and that after treatment of
MDA-MB-468 cells with IC10 and IC20 doses of trastuzu-
mab for 4 h, 2 days, 4 days and 6 days relative to untreated
cells are shown in Fig. 3. Incorporation of FDG by SKBr3
cells was not significantly decreased by treatment with
trastuzumab for 4 h with IC20 and IC50 doses (t6=0.56, ns;
t6=0.21, ns) and 2 days with IC20 dose (t28=0.29, ns) but was
increased with IC50 dose for 2 days (t28=4.87, Pb.001) and
decreased after treatment for 4 days (t22=2.4, Pb.05) and
6 days (t30=2.18, Pb.05) with IC50 dose and 4 days
(t22=2.03, Pb.05) with IC20 dose of trastuzumab by the
SKBr3 cells. Incorporation of FDG by trastuzumab-treated
MDA-MB-453 cells was not significantly changed by IC20
dose for 4 h (t14=1.22, ns), 2 days (t21=1.55, ns), 4 days
(t12=0.44, ns) and 6 days (t12=0.36, ns) but was significantly
decreased by treatment with IC50 dose for 4 h (t14=2.83,
Pb.01), 2 days (t21=2.07, Pb.05), 4 days (t12=2.59, Pb.05)∗
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Fig. 3. FDG incorporation per milligram of protein after trastuzumab
treatment with (A) SKBr3 [IC20 (hatched symbols) and IC50 (squares)],
(B) MDA-MB-453 [IC20 (hatched symbols) and IC50 (squares)] and (C)
MDA-MB-468 [IC10 (hatched symbols) and IC20 (squares)]. FDG uptake
per flask was normalized to protein content. Normalized uptake by treated
cells is expressed relative to normalized uptake by control cells (%). The
asterisks indicate significant difference from control at ⁎Pb.05 and
⁎⁎Pb.01.
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Fig. 4. (A, B) HK activity (A) and glucose transport (B) by SKBr3 (dots),
MDA-MB-453 (squares) and MDA-MB-468 (hatched symbols) cells treated
with IC50, IC50 and IC20 doses, respectively, of trastuzumab. Absorbance
change per minute (due to NADPH formation) normalized to protein
content. Normalized HK activity by treated cells is expressed relative to
normalized activity by control cells (%). The double asterisk indicates
significant difference from control at Pb.01.
343R.W. Cheyne et al. / Nuclear Medicine and Biology 38 (2011) 339–346and 6 days (t16=6.2, Pb.01). FDG incorporation was
decreased in MDA-MB-468 cells after 4 days (t18=2.78,
Pb.01) and 6 days of treatment with both the IC20 dose
(t11=3.01, Pb.01) and the IC10 dose (t11=2.12, Pb.05) of
trastuzumab. The lower doses of trastuzumab did not
significantly decrease FDG incorporation at earlier time
points of 4 h (t21=1.7, ns), 2 days (t14=1.62, ns) and 4 days
(t18=0.18, ns).
HK activity in homogenates prepared from SKBr3,
MDA-MB-453 and MDA-MB-468 treated with trastuzumab
for 6 days using IC50 doses is shown in Fig. 4A as a
percentage of HK activity in respective untreated cells.
The activity of HK is significantly decreased by SKBr3
(t10=5.64, Pb.001), MDA-MB-453 (t10=5.78, Pb.001) andMDA-MB-468 (t28=2.96, Pb.005) cells after treatment with
trastuzumab compared with control cells. As FDG incorpo-
ration was decreased after 4 h of treatment by MDA-MB-453
cells with trastuzumab, HK activity was measured and found
to be significantly (t8=2.36, Pb.02) decreased by about 20%
compared with control cells [4 h of trastuzumab treatment,
57 (±5.8) mU/min/mg of protein; controls, 72 (±12.7) mU/
min/mg of protein].
Fig. 4B shows the uptake of [3H]OMG by untreated cells
incubated with [3H]OMG (with 0.1 mM OMG) for 5 s and
by cells treated with IC50 (SKBr3 and MDA-MB-453) and
IC20 (MDA-MB-468) doses of trastuzumab for 6 days. ([
3H]
OMG uptake by control cells incubated for10 s with OMG is
also given to show that the uptake of OMG had not reached
equilibrium at 5 s.) Glucose transport was found to be
significantly decreased by MDA-MB-453 (t19=2.74, Pb.01),
but not by MDA-MB-468 (t6=0.98, ns) and SKBr3 (t6=1.32,
ns), cells treated for 6 days with trastuzumab compared with
untreated cells.
Lactate production was measured in each cell line after
treatment for 6 days with IC50 doses of trastuzumab. The
results in Fig. 5 show that treatment with trastuzumab is
accompanied by significant decreases in lactic acid produc-
tion by SKBr3 (t6=2.45, Pb.05) and MDA-MB-453
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Fig. 5. Lactate production by SKBr3 (dots), MDA-MB-453 (squares) and
MDA-MB-468 (hatched symbols) cells treated with IC50, IC50 and IC20
doses, respectively, of trastuzumab. Lactate production by treated cells is
expressed relative to control cells (%).The asterisks indicate significant
difference from control at ⁎Pb.05 and ⁎⁎Pb.01.
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(t12=0.41, ns) (Table 2).4. Discussion
The purpose of this study was to determine how FDG
incorporation was modulated during response of breast
tumor cells to treatment with trastuzumab, which targets
HER-2. Three tumor cell lines expressing HER-2 at high,
medium and low/negative levels were employed in this
study in common with controls utilized in studies of the
assessment of suitability of breast tumors for treatment with
trastuzumab [13].
In the clinic, trastuzumab is administered to patients on a
weekly basis, maintaining a steady-state serum concentration
of 50–60 μg/ml [14]. Sensitivity of cells to trastuzumab was
determined using the MTT assay after drug exposure over a
6-day period as shorter exposure times did not produce a
dose inhibition of 50% even in the most sensitive cell line
(SKBr3). The dose of trastuzumab causing 50% growth
inhibition was lowest for the SKBr3 cells, which exhibit the
greatest overexpression of HER-2 [15]. Growth inhibition of
MDA-MB-468 cells, which express normal levels of HER-2,
was observed with a 10% inhibition using a dose of 5 μg/ml
and 20% using 170 μg/ml. Thus, according to the MTT
assay, clinically relevant doses of 50–60 μg/ml would result
in some growth inhibition of tumor cells that do not
overexpress HER-2.
Although the MTT assay is effective in demonstrating
sensitivity of cells to a drug, it is a measure of mitochondrial
oxidative potential and utilized as a measure of cell number
but does not reveal whether or not those cells are fully
functional in terms of long-term proliferative ability.
Furthermore, some drug treatments influence mitochondrial
oxidative potential. The colony-forming assay, on the other
hand, measures a drug's ability to induce clonogenic cell
death [16,17]. With the use of this assay, continuous
exposure to trastuzumab for 7 and 10 days was found to
have produced only a marginal decrease in colony formation
after treatment of MDA-MB-468 cells with the apparentIC20 determined using the MTT assay, suggesting that
treatment with trastuzumab would not be therapeutically
effective as expected for HER-2-negative cells. Continuous
exposure of SKBr3 and MDA-MB-453 cells to trastuzumab
appreciably decreased their proliferative capacity, concur-
ring with the MTT results and demonstrating the effective-
ness of trastuzumab therapy for HER-2-overexpressing
tumor cells.
In terms of HER-2 expression, MDA-MB-453 cells are
considered to be 2+ [18], which is the minimum expression
by breast tumors for which trastuzumab is clinically utilized.
Cells that were sensitive to trastuzumab (SKBr3) exhibited
decreased FDG incorporation relative to untreated cells
when treated with IC50 doses of trastuzumab for 4 and 6
days. However, MDA-MB-453 cells, which exhibit lower
HER-2 expression and are less sensitive to trastuzumab,
exhibited greater decreases in incorporation and at earlier
time points.
The response of SKBr3 cells to trastuzumab was
accompanied at 2 days by increased FDG incorporation
before declining to below control levels. This may reflect an
early stimulatory effect of trastuzumab on SKBr3 cells.
Metabolic flare is more commonly associated with tamox-
ifen treatment [19]; however, two studies [20,21] have
reported that exposure of tumor cells, including SKBr3
cells, to trastuzumab results in an initial stimulatory
phosphorylation of HER-2. Cell death has also been shown
to be associated with an early increase in FDG incorpora-
tion. Thus, Aide et al. [22] recently showed that FDG
incorporation increased 2 days after treatment of testicular
tumor xenografts with cisplatin before decreasing at longer
time points, which was attributed to events associated with
cell death.
Changes in FDG incorporation have been documented
in xenografts and in patients responding to the tyrosine
kinase inhibitors CI-1033 [23] and lapatinib [24], respec-
tively, which inhibit the epidermal growth factor receptor
tyrosine kinases ErbB1 and ErbB2 downstream from HER-1
and HER-2. In a study of eight patients with various solid
tumors, one patient who had trastuzumab-resistant Her-2 3+
tumor exhibiting a partial response showed the greatest
decrease in FDG incorporation 1 month after the start of
treatment [24].
The present study found that decreases at 6 days (and at
4 h of treatment with MDA-MB-453 cells) in FDG
incorporation corresponded with decreased HK activity.
HK expression is increased by activation of the EGFR/ErbB
pathway [25], so inhibition would be expected to decrease
incorporation as observed in the present study. These
findings also suggest that HK activity in these breast tumor
cell lines may be rate-limiting for FDG incorporation,
concurring with studies on breast cancer patients [26].
FDG incorporation measures the rate of glucose utiliza-
tion via glycolysis. The product of glycolysis, pyruvate, can
either be converted to acetyl-CoA and enter the tricarboxylic
acid cycle or be converted to lactic acid. Lactate levels in
345R.W. Cheyne et al. / Nuclear Medicine and Biology 38 (2011) 339–346tumors can be monitored using 1H NMR imaging, and
studies have shown using this technique that response to
therapy can be accompanied by decreased levels of lactic
acid [27]. Thus, Lee et al. [27] showed that response to
treatment of xenografts derived from WSU-DLCL2 non-
Hodgkin's lymphoma cells with a combination of rituximab,
cyclophosphamide, hydroxydoxorubicin, vincristine and
prednisone exhibited decreased lactate levels. On the other
hand, the use of hyperpolarized 13C-labeled pyruvate
utilization [28] has shown decreased flux of the hyperpolar-
ized 13C label between pyruvate and lactate, corresponding
with decreased FDG uptake by murine lymphoma cells after
treatment for 24 h with the topoisomerase II inhibitor,
etoposide. In the present study, both SKBr3 and MDA-MB-
453 cells exhibited significant decreases in lactate produc-
tion after treatment with trastuzumab for 6 days, suggesting
that following lactate production, pre- and post-treatment
may be useful in predicting response to anti-HER-2
antibody treatment.
High doses of trastuzumab were found to induce a
moderate growth-inhibitory effect on MDA-MB-468 cells
and to significantly decrease FDG incorporation by this cell
line, although only by about 10% and at later time points.
This could be attributed to an interruption of the pairing
effect of HER-2 with other HER receptors by trastuzumab
[29,30].
In conclusion, changes in FDG incorporation at the cell
level by breast tumor cells correspond with response to IC50
doses of the anti-HER-2 antibody trastuzumab. The
sensitivity of HK to this drug underlies the reduction in
FDG incorporation. Decreased lactate production may be a
useful indicator of response to trastuzumab.Acknowledgments
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